CA9, CYFIP2 and LGALS3BP-A Novel Biomarker Panel to Aid Prognostication in Glioma

Simple Summary Glioma is a deadly disease with few treatment options. Early detection of recurrence and progression will help in the clinical management of glioma patients. Biomarkers or molecules that can accurately predict clinical outcomes are becoming extremely important. This study aimed to identify biomarkers of progression and overall survival in glioma. A three-protein panel that could accurately distinguish between long and short survival was identified. Incorporating such biomarkers into clinical practice could significantly aid clinical management.Abstract Brain cancer is a devastating and life-changing disease. Biomarkers are becoming increasingly important in addressing clinical issues, including in monitoring tumour progression and assessing survival and treatment response. The goal of this study was to identify prognostic biomarkers associated with glioma progression. Discovery proteomic analysis was performed on a small cohort of astrocytomas that were diagnosed as low-grade and recurred at a higher grade. Six proteins were chosen to be validated further in a larger cohort. Three proteins, CA9, CYFIP2, and LGALS3BP, were found to be associated with glioma progression and, in univariate analysis, could be used as prognostic markers. However, according to the results of multivariate analysis, these did not remain significant. These three proteins were then combined into a three-protein panel. This panel had a specificity and sensitivity of 0.7459 for distinguishing between long and short survival. In silico data confirmed the prognostic significance of this panel.